Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
1991-8-23
pubmed:abstractText
The effects of changes in pH on the binding of agonists and antagonists to the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor were determined. Competition binding studies were performed with the TXA2/PGH2 mimetic [1S-1 alpha,2 beta (5Z), 3 alpha(1E,3R*),4 alpha)]-7-[3-(3-hydroxy-4'-iodophenoxy)-1-buteny) 7-oxabicyclo-[2.2.1]-heptan-2-yl]-5-heptenoic acid ([125I]BOP). The pH optimum for binding of [125I] BOP to washed human platelets was broad with a range of pH 4-6 in contrast to that of the TXA2/PGH2 receptor antagonist 9,11-dimethyl-methano-11,12-methano-16-(3-iodo-4-hydroxyl)-13-aza-15 alpha,beta-omega-tetranorthromboxane A2 ([125I]PTA-OH) which was 7.4. Scatchard analysis of [125I]BOP binding in washed platelets at pH 7.4, 6.0, and 5.0 revealed an increase in affinity (Kd = 1.16 +/- 0.06, 0.64 +/- 0.09, and 0.48 +/- 0.05 nM, respectively) and an increase in the number of receptors (Bmax = 2807 +/- 415, 5397 +/- 636, and 7265 +/- 753 sites/platelet, respectively). The potency of I-BOP to induce shape change in washed platelets at pH 6.0 was also significantly increased from an EC50 value of 0.34 +/- 0.016 nM at pH 7.4 to 0.174 +/- 0.014 nM at pH 6.0 (n = 6, p less than 0.05). In contrast, the EC50 value for thrombin was unaffected by the change in pH. In competition binding studies with [125I]BOP, the affinity of the agonists U46619 and ONO11113 were increased at pH 6.0 compared to 7.4. In contrast, the affinity of the TXA2/PGH2 receptor antagonists I-PTA-OH, SQ29548, and L657925 were either decreased or unchanged at pH 6.0 compared to 7.4. Diethyl pyrocarbonate and N-bromosuccinimide, reagents used to modify histidine residues, reversed the increase in affinity of [125I]BOP at pH 6.0 to values equivalent to those at pH 7.4. In solubilized platelet membranes, the effects of NBS were blocked by coincubation with the TXA2/PGH2 mimetic U46619. The results suggest that agonist and antagonist binding characteristics are different for the TXA2/PGH2 receptor and that histidine residue(s) may play an important role in the binding of TXA2/PGH2 ligands to the receptor.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/15-Hydroxy-11 alpha,9..., http://linkedlifedata.com/resource/pubmed/chemical/7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1..., http://linkedlifedata.com/resource/pubmed/chemical/Bicyclo Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Bicyclo Compounds, Heterocyclic, http://linkedlifedata.com/resource/pubmed/chemical/Bromosuccinimide, http://linkedlifedata.com/resource/pubmed/chemical/Carbazoles, http://linkedlifedata.com/resource/pubmed/chemical/Diethyl Pyrocarbonate, http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Unsaturated, http://linkedlifedata.com/resource/pubmed/chemical/Histidine, http://linkedlifedata.com/resource/pubmed/chemical/Hydrazines, http://linkedlifedata.com/resource/pubmed/chemical/I-PTA-OH, http://linkedlifedata.com/resource/pubmed/chemical/Ligands, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin Endoperoxides..., http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Prostaglandin, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane A2..., http://linkedlifedata.com/resource/pubmed/chemical/SQ 29548, http://linkedlifedata.com/resource/pubmed/chemical/STA 2, http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
266
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
13752-8
pubmed:dateRevised
2009-2-14
pubmed:meshHeading
pubmed-meshheading:1830308-15-Hydroxy-11 alpha,9..., pubmed-meshheading:1830308-Bicyclo Compounds, pubmed-meshheading:1830308-Bicyclo Compounds, Heterocyclic, pubmed-meshheading:1830308-Blood Platelets, pubmed-meshheading:1830308-Bromosuccinimide, pubmed-meshheading:1830308-Carbazoles, pubmed-meshheading:1830308-Cell Membrane, pubmed-meshheading:1830308-Diethyl Pyrocarbonate, pubmed-meshheading:1830308-Fatty Acids, Unsaturated, pubmed-meshheading:1830308-Histidine, pubmed-meshheading:1830308-Humans, pubmed-meshheading:1830308-Hydrazines, pubmed-meshheading:1830308-Hydrogen-Ion Concentration, pubmed-meshheading:1830308-Kinetics, pubmed-meshheading:1830308-Ligands, pubmed-meshheading:1830308-Platelet Activation, pubmed-meshheading:1830308-Prostaglandin Endoperoxides, Synthetic, pubmed-meshheading:1830308-Protein Binding, pubmed-meshheading:1830308-Receptors, Prostaglandin, pubmed-meshheading:1830308-Receptors, Thromboxane, pubmed-meshheading:1830308-Receptors, Thromboxane A2, Prostaglandin H2, pubmed-meshheading:1830308-Solubility, pubmed-meshheading:1830308-Thromboxane A2
pubmed:year
1991
pubmed:articleTitle
Differential effect of pH on thromboxane A2/prostaglandin H2 receptor agonist and antagonist binding in human platelets.
pubmed:affiliation
Department of Cell and Molecular Pharmacology, and Experimental Therapeutics, Medical University of South Carolina, Charleston 29425.
pubmed:publicationType
Journal Article, In Vitro